ORG Wealth Partners LLC Makes New $273,000 Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• ORG Wealth Partners LLC has invested $273,000 in IDEXX Laboratories by acquiring 504 shares, according to their recent SEC filing.
• Several hedge funds, including Vanguard Group and Price T Rowe Associates, have increased their stakes in IDEXX Laboratories, with institutional investors owning 87.84% of the company.
• IDEXX Laboratories recently reported a quarterly earnings per share (EPS) of $3.63, exceeding estimates and showcasing a 10.6% year-over-year revenue increase.

ORG Wealth Partners LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 504 shares of the company's stock, valued at approximately $273,000.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of IDEXX Laboratories by 1.5% in the first quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company's stock valued at $4,139,001,000 after acquiring an additional 146,427 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company's stock valued at $835,244,000 after acquiring an additional 825,965 shares during the period. Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 0.5% in the first quarter. Invesco Ltd. now owns 1,166,406 shares of the company's stock valued at $489,832,000 after acquiring an additional 5,418 shares during the period. Principal Financial Group Inc. boosted its position in shares of IDEXX Laboratories by 58.3% in the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after acquiring an additional 414,802 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of IDEXX Laboratories by 37.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company's stock valued at $452,046,000 after acquiring an additional 290,551 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other news, EVP Michael Lane sold 8,411 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares of the company's stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total value of $18,491,734.80. Following the completion of the transaction, the chief executive officer directly owned 83,311 shares of the company's stock, valued at approximately $52,650,885.78. The trade was a 25.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock worth $34,293,468 in the last three months. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Up 2.3%

IDXX stock opened at $632.22 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The business has a 50 day moving average price of $625.60 and a two-hundred day moving average price of $528.15. The company has a market cap of $50.58 billion, a price-to-earnings ratio of 52.64, a P/E/G ratio of 4.09 and a beta of 1.56. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of a number of recent research reports. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. Piper Sandler reiterated a "neutral" rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Morgan Stanley increased their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research note on Friday, August 15th. BTIG Research increased their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Finally, Wall Street Zen cut IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.